Imfinzi demonstrated statistically significant and clinically meaningful improvement in EFS and OS for MIBC in NIAGARA Ph 3 trial July 1, 2024
FAILED TRIAL: Ph 3 PRESERVE 2 Trial of Trilaciclib Before 1L chemo in mTNBC did Not Achieve Statistical Significance in the Primary Endpoint of OS July 1, 2024
Initial Safety and Efficacy Data from Ph 1 Trial of WTX-330 in Patients with Advanced or Metastatic Solid Tumors or NHL announced July 1, 2024
Positive Topline Results from TACTI-003 Ph 2b Trial in 1L Head and Neck Cancer announced July 1, 2024
Updated Interim Ph 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic HNSCC reported July 1, 2024
Substantial OS Benefit and Unprecedented DoR in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Ph 2 Study in 1L Pancreatic Cancer Announced July 1, 2024
Positive Initial Data Announced from Ph 1 MINOTAUR Trial of Lunresertib in Combination with FOLFIRI July 1, 2024
Stenoparib Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer in Ph 2 clinical trial July 1, 2024
FAILED TRIAL: ADJUVANT BR.31 Ph 3 trial of Imfinzi (durvalumab) did not achieve statistical significance for the primary endpoint of DFS vs placebo in early-stage (IB-IIIA) NSCLC July 1, 2024
New Survival Data for Amezalpat (TPST-1120) in 1L HCC Study Demonstrated a Six-Month Improvement over Control Arm June 25, 2024
FAILED TRIAL: CAPItello-290 Ph 3 trial of Truqap (capivasertib) + chemo in locally advanced, inoperable or metastatic TNBC patients with PI3KCA/AKT1/PTEN alterations did not meet the dual primary endpoints of OS improvement June 25, 2024
Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Ph 1/2 Clinical Trial of MB-106 Announced June 25, 2024
Data from 1-BETTER Ph 1/2 study for advanced pancreatic cancer of Natrunix + ONIVYDE/5-FU announced June 25, 2024
100% Partial Response or Better Announced in Multiple Myeloma Patients in Interim, Top-line Data from STAR-LLD Ph 1b Trial June 25, 2024
Unprecedented 82.3% DOR at 12 Months in the ENVISION Trial Investigating UGN-102 as a Non-Surgical Treatment for LG-IR-NMIBC announced June 18, 2024
Calquence + chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. SOC in patients with untreated mantle cell lymphoma in ECHO Ph 3 trial June 18, 2024
Positive Topline Results from Ph 2 PICCOLO Trial of Mirvetuximab Soravtansine (ELAHERE) for High FRα Expressing Platinum-Sensitive Ovarian Cancer Announced June 11, 2024
Tisotumab Vedotin Ph 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic HNSCC June 11, 2024
3-Year Data For mRNA-4157 (V940) + KEYTRUDA Demonstrated Sustained Improvement in RFS & Distant MFS vs KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection June 11, 2024
FAILED TRIAL: Uproleselan failed to demonstrate significant OS improvement for patients with primary refractory AML in pivotal Ph 3 trial June 11, 2024
